These results provide the initial evidence that a non-classical TLR4 complex is activated by a matrikine endogenously enriched in certain MM patients and further credence to the rationale that therapeutically targeting TLR4 may help inhibit MM progression. This evidence concerns the gene TLR4 and Miyoshi myopathy.